Oncotarget

Brief Reports:

Mutant IDH1 is required for IDH1 mutated tumor cell growth

PDF  |  HTML  |  How to cite

Oncotarget. 2012; 3:774-782. https://doi.org/10.18632/oncotarget.577

Metrics: PDF 3792 views  |   HTML 4076 views  |   ?  

Genglin Jin1, Christopher J. Pirozzi1, Lee H. Chen1, Giselle Y. Lopez1, Christopher G. Duncan1, Jie Feng1, Ivan Spasojevic2, Darell D. Bigner1, Yiping He1, and Hai Yan1

1 The Preston Robert Tisch Brain Tumor Center, The Pediatric Brain Tumor Foundation Institute, and The Department of Pathology,

2 The Clinical Pharmacology Laboratory, Duke Cancer Institute and Department of Medicine/Oncology, Duke University Medical Center, Durham, North Carolina, USA

Correspondence:

Hai Yan, email: hai.yan@duke.edu

Keywords: IDH1, cell survival

Received: July 27, 2012, Accepted: August 04, 2012, Published: August 09, 2012

Abstract

Frequent somatic hotspot mutations in isocitrate dehydrogenase 1 (IDH1) have been identified in gliomas, acute myeloid leukemias, chondrosarcomas, and other cancers, providing a likely avenue for targeted cancer therapy. However, whether mutant IDH1 protein is required for maintaining IDH1 mutated tumor cell growth remains unknown. Here, using a genetically engineered inducible system, we report that selective suppression of endogenous mutant IDH1 expression in HT1080, a fibrosarcoma cell line with a native IDH1R132C heterozygous mutation, significantly inhibits cell proliferation and decreases clonogenic potential. Our findings offer insights into changes that may contribute to the inhibition of cell proliferation and offer a strong preclinical rationale for utilizing mutant IDH1 as a valid therapeutic target.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 577